Update on Migraine Prophylaxis: Things that can help your migraine patients

Main Article Content

Kiratikorn Vongvaivanich, MD

Abstract

Migraine is a common chronic neurological disorder characterized by recurrent episodes of disabling headaches. It is also known as one of the most debilitating disorders. Approximately 90% of migraineurs experience moderate  to severe pain, and 75% have impaired function during migraine attacks and 53% reported severe impairment or require bed rest during their attacks.1,2 Approximately one third of migraineurs had missed at least one day of work or school in the last year and often have decreased productivity by at least one half.3-5 Hypersensitivity to light (photophobia), sound (phonophobia), smell (osmophobia), and head movement, along with nausea and vomiting are associated with the attack.

Downloads

Download data is not yet available.

Article Details

How to Cite
1.
Vongvaivanich K. Update on Migraine Prophylaxis: Things that can help your migraine patients. BKK Med J [Internet]. 2013Feb.20 [cited 2020Jul.16];50:50. Available from: https://he02.tci-thaijo.org/index.php/bkkmedj/article/view/218089
Section
Reviews Article

References

1. Lipton RB, Bigal ME, Diamond M, et al, for the AMPP Advisory Group. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology 2007; 68:343-9.
2. Lipton RB, Stewart WF, Diamond S, et al. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache 2001;41:646-57.
3. Ferrari MD. The economic burden of migraine to society.Pharmacoeconomics 1998;13:667-76.
4. Stewart WF, Lipton RB, Simon D. Work-related disability: results from the American Migraine study. Cephalalgia 1996;16:231-8.
5. Michel P, Dartigues JF, Lindousli A, et al. Loss of produc- tivity and quality of life in migraineurs among French workers: results from the GAZEL cohort. Headache 1997;37:71-8.
6. Headache Classification Committee of the International Headache Society, The International Classification of Headache Disorders: 2nd edition, Cephalalgia 2004;24 (Suppl 1):9-160.
7. Schoenen J. Neurophysiological features of the migrainous brain. Neurol Sci 2006;27:77-81.
8. Olesen J, Burstein R, Ashina M, et al. Origin of pain in migraine: evidence for peripheral sensitisation. Lancet Neurol 2009; 8:679-90.
9. Maizels M, Aurora S, Heinricher M. Beyond Neurovas- cular: Migraine as a Dysfunctional Neurolimbic Pain Network. Headache 2012 Jul 3. doi: 10.1111/j.1526-4610. 2012.02209.x. [Epub ahead of print]
10. Mainero C, Boshyan J, Hadjikhani N. Altered functional magnetic resonance imaging resting-state connectivity in periaqueductal gray networks in migraine. Ann Neurol 2011;70:838-45.
11. Leonardi M, Steiner TJ, Scher AI, et al. The global burden of migraine: measuring disability in headache disorders with WHO’s Classification of Functioning, Disability and Health (ICF). J Headache and Pain 2005; 6:429-40.
12. Stovner Lj, Hagen K, Jensen R, et al. The global burden of headache: a documentation of headache prevalence and disability worldwide. Cephalalgia 2007;27:193-210.
13. Edmeads J, Mackell JA. The economic impact of migraine: an analysis of direct and indirect costs. Headache 2002;42:501-9.
14. Ferrari MD. The economic burden of migraine to society.Pharmacoeconomics 1998;13:667-76.
15. Stewart WF, Lipton RB, Simon D. Work-related disability: results from the American Migraine study. Cephalalgia 1996;16:231-8.
16. Michel P, Dartigues JF, Lindousli A, et al. Loss of produc- tivity and quality of life in migraineurs among French workers: results from the GAZEL cohort. Headache 1997;37:71-8.
17. Silberstein SD, Winner PK, Chmiel JJ. Migraine preventive medication reduces resource utilization. Headache 2003;43:171-8.
18. Silberstein SD. Preventive treatment of migraine: an overview. Cephalalgia 1997;17:67-72.
19. Brown JS, Papadopoulos G, Neumann PJ, et al. Cost-effectiveness of topiramate in migraine prevention: Results from a pharmacoeconomic model of topiramate treatment. Headache 2005;45:1012-22.
20. D’Amico D, Solari A, Usai S, et al. Improvement in quality of life and activity limitations in migraine patients after prophylaxis. A prospective longitudi- nal multicentre study. Cephalalgia 2006;26:691-6.
21. Silberstein SD, for the US Headache Consortium Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000;55:754-62.
22. Silberstein SD, Rosenberg J. Multispecialty consensus on diagnosis and treatment of headache. Neurology 2000;54: 1553.
23. Schroeder BM. AAFP/ACP-ASIM release guidelines on the management and prevention of migraines. Am Fam Physician 2003;67:1392,1395-7.
24. Evers S, Afra J, Frese A, et al. European Federation of Neurological Societies. EFNS guideline on the drug treatment of migraine--revised report of an EFNS task force. Eur J Neurol 2009;16:968-81.
25. Bigal ME, Lipton RB. Migraine chronification. Curr Neurol Neurosci Rep 2011;11(2):139-48.
26. Evans RW, Loder E, Biondi DM. When can successful migraine prophylaxis be discontinued? Headache 2004; 44:1040-2.
27. Lipton RB. Tracing transformation:chronic migraine classification,progression, and epidemiology.Neurology 2009;72(Suppl 5):S3-7.
28. Bigal ME, Serrano D, Buse D, et al. Acute migraine medications and evolution from episodic to chronic migraine: a longitudinal population-based study. Headache 2008;48:1157-68.
29. Bigal ME, Lipton RB, Holland PR, et al. Obesity, migraine, and chronic migraine: possible mechanisms of interaction. Neurology 2007;68:1851-61.
30. Scher AI, Lipton RB, Stewart WF. Habitual snoring as a risk factor for chronic daily headache. Neurology 2003;60:1366-8.
31. Scher AI, Stewart WF, Buse D, et al. Major life changes before and after the onset of chronic daily headache: a population-based study. Cephalalgia 2008;28:868-76.
32. Silberstein SD, Holland S, Freitag F, et al. Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology 2012;78:1337-45.
33. Holland S, Silberstein SD, Freitag F, et al. Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Evidence-based guideline update: NSAIDs and other complementary treatments for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology 2012;78: 1346-53.
34. Mulleners WM, Chronicle EP. Anticonvulsants in migraine prophylaxis: a Cochrane review. Cephalalgia 2008;28: 585-97.
35. Dodgson SJ, Shank RP, Maryanoff BE. Topiramate as an inhibitor of carbonic anhydrase isoenzymes. Epilepsia 2000;41(Suppl 1):S35-9.
36. Andreou AP, Goadsby PJ. Topiramate in the treatment of migraine: a kainate (glutamate) receptor antagonist within the trigeminothalamic pathway. Cephalalgia 2011;31: 1343-58.
37. Schürks M, Diener HC, Goadsby P. Update on the prophylaxis of migraine. Curr Treat Options Neurol 2008; 10:20-9.
38. Pringsheim T, Davenport WJ, Becker WJ. Prophylaxis of migraine headache. CMAJ 2010;182:E269-76.
39. Barbanti P, Aurilia C, Egeo G, et al. Migraine prophylaxis: what is new and what we need? Neurol Sci 2011;32 (Suppl 1):S111-5.
40. Margulis AV, Mitchell AA, Gilboa SM, et al. National Birth Defects Prevention Study. Use of topiramate in pregnancy and risk of oral clefts. Am J Obstet Gynecol 2012;207:405.e1-7.
41. Abtahi MA, Abtahi SH, Fazel F, et al. Topiramate and the vision: a systematic review. Clin Ophthalmol 2012;6: 117-31.
42. Vikelis M, Rapoport AM. Role of antiepileptic drugs as preventive agents for migraine. CNS Drugs 2010;24: 21-33.
43. Silberstein SD, Wilmore LJ. Divalproex sodium: migraine treatment and monitoring. Headache 1996;36:239-42.
44. Galletti F, Cupini LM, Corbelli I, et al. Pathophysiological basis of migraine prophylaxis. Prog Neurobiol 2009;89: 176-92.
45. Linde K, Rossnagel K. Propranolol for migraine prophy- laxis. Cochrane Database Syst Rev 2004;CD003225.
46. Diener HC, Matias-Guiu J, Hartung E, et al. Efficacy and tolerability in migraine prophylaxis of flunarizine in reduced doses: a comparison with propranolol 160 mg daily. Cephalalgia 2002;22:209-21.
47. Leone M, Grazzi L, Mantia LL, et al. Flunarizine in migraine: a mini review. Headache 1991;31: 388-91.
48. Diener H, Matias-Guiu J, Hartung E, et al. Efficacy and tolerability in migraine prophylaxis of flunarizine in reduced doses: a comparison with propranolol 160 mg daily. Cephalalgia 2002;22:209-21.
49. Reveiz-Herault L, Cardona AF, Ospina EG, et al. Effec- tiveness of flunarizine in the prophylaxis of migraine: a meta-analytical review of the literature. Rev Neurol 2003;36:907-12.
50. Jackson JL, Shimeall W, Sessums L, et al. Tricyclic antidepressants and headaches: systematic review and meta-analysis. BMJ 2010;341:c5222.
51. Couch JR. Amitriptyline Versus Placebo Study Group. Amitriptyline in the prophylactic treatment of migraine and chronic daily headache. Headache 2011;51:33-51.
52. Ozyalcin SN, Talu GK, Kiziltan E, et al. The efficacy and safety of venlafaxine in the prophylaxis of migraine. Headache 2005;45:144-52.
53. Milla´n-Guerrero RO, Isais-Milla´n R, Benjamín TH, et al. N-alpha-methyl histamine safety and efficacy in migraine prophylaxis: phase III study. Can J Neurol Sci 2006;33:195-9.
54. Milla´n-Guerrero RO, Isais-Milla´n R, Barreto-Vizcaíno S, et al. Subcutaneous histamine versus sodium valproate in migraine prophylaxis: a randomized, controlled, doubleblind study. Eur J Neurol 2007;14:1079-84.
55. Milla´n-Guerrero RO, Isais-Milla´n R, Barreto-Vizcaíno S, et al. Subcutaneous histamine versus topiramate in migraine prophylaxis: a double-blind study. Eur Neurol 2008;59:237-42.
56. Rao BS, Das DG, Taraknath VR, et al. A double blind controlled study of propranolol and cyproheptadine in migraine prophylaxis. Neurol India 2000;48:223-6.
57. Welch KMA: Naproxen sodium in the treatment of migraine. Cephalalgia 1986;6:85-92.
58. Diener HC, Hartung E, Chrubasik J, et al. A comparative study of acetylsalicyclic acid and metoprolol for the prophylactic treatment of migraine. A randomised, controlled, double-blind, parallel group phase III study. Cephalalgia 2001;21:140-4.
59. Benseñor IM, Cook NR, Lee IM, et al. Low-dose aspirin for migraine prophylaxis in women.Cephalalgia 2001;21: 175-83.
60. Schrader H, Stovner LJ, Helde G, et al. Prophylactic treatment of migraine with angiotensin converting enzyme inhibitor (lisinopril): randomised, placebo controlled, crossover study. BMJ 2001;322:19-22.
61. Tronvik E, Stovner L, Helde G, et al. Prophylactic treatment of migraine with an angiotensin II receptor blocker: a randomized controlled trial. JAMA 2003;289: 65-9.
62. Grossman W, Schmidramsl H. An extract of Petasites hybridus is effective in the prophylaxis of migraine. Altern Med Rev 2001;6:303-10.
63. Lipton RB, Gobel H, Einhaupl KM, et al. Petasites hybridus root (butterbur) is an effective preven-tive treatment for migraine. Neurology 2004;63:2240-4.
64. Pfaffenrath V, Diener HC, Fischer M, et al. The efficacy and safety of Tanacetum parthenium (feverfew) in migraine prophylaxis–a double-blind, multicentre, randomized placebo- controlled dose-response study. Cephalalgia 2002;22:523-32.
65. Diener HC, Pfaffenrath V, Schnitker J, et al. Efficacy and safety of 6.25 mg tid feverfew CO2-extract (MIG-99) in migraine prevention–a randomized, double-blind, multicentre, placebo-controlled study. Cephalalgia 2005; 25:1031-41.
66. Watanabe H, Kuwabara T, Ohkubo M, et al. Elevation of cerebral lactate detected by localized 1H-magnetic resonance spectroscopy in migraine during the interictal period. Neurology 1996;47:1093-5.
67. Penn AMW, Lee JWK, Thuillier P, et al. MELAS syndrome with mitochondrial tRNALeu (UUR) mutation: correlation of clinical state, nerve conduction, and muscle 31P magnetic resonance spectroscopy during treatment with nicotinamide and riboflavin. Neurology 1992;42: 2147-52.
68. Nishikawa Y, Takahashi M, Yorifuji S, et al. Long-term coenzyme Q10 therapy for a mitochondrial encephalomy- opathy with cytochrome c oxidase deficiency: a 31P NMR study. Neurology 1989;39:399-403.
69. Montagna P. High-dose riboflavin as a prophylactic treatment. Cephalalgia 1994;14:317.
70. Schoenen J, Jacquy J, Lenaerts M. Effectiveness of high-dose riboflavin in migraine prophylaxis. A randomized controlled trial. Neurology 1998;50:466-70.
71. Peikert A, Wilimzig C, Köhne-Volland R. Prophylaxis of migraine with oral magnesium: results from a prospective, multi-center, placebo-controlled and double-blind randomized study. Cephalalgia 1996;16: 257-63.
72. Maizels M, Blumenfeld A, Burchette R. A combination of riboflavin, magnesium, and feverfew for migraine prophylaxis: a randomized trial. Headache 2004;44: 885-90.
73. Hershey AD, Powers SW, Vockell A-LB, et al. Coenzyme Q10 deficiency and response to supplementation in pediatric and adolescent migraine. Headache 2007;47: 73-80.
74. Rozen TD, Oshinsky ML, Gebeline CA, et al. Open label trial of coenzyme Q10 as a migraine preventive. Cephalalgia 2002;22:137-41.
75. Sándor PS, Di Clemente L, Coppola G, et al. Efficacy of coenzyme Q10 in migraine prophylaxis: a randomized controlled trial. Neurology 2005;64:713-5.
76. Simpson LL.The origin,structure,and pharmacological activity of botulinum toxin.Pharmacol Rev1981;33:155-88.
77. Cui M, Khanijou S, Rubino J, et al. Subcutaneous administration of botulinum toxin A reduces formalin-induced pain. Pain 2004;107(1-2):125-33.
78. Aoki KR. Review of a proposed mechanism for the antinociceptive action of botulinum toxin type A. Neurotoxicology 2005;26(5):785-93.
79. Olesen J, Bousser MG, Diener HC, et al. New appendix criteria open for a broader concept of chronic migraine. Cephalalgia 2006;26:742-6.
80. Aurora SK, Dodick DW, Turkel CC, et al. PREEMPT 1 Chronic Migraine Study Group. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial. Cephalalgia 2010;30:793-803.
81. Diener HC, Dodick DW, Aurora SK, et al. PREEMPT 2 Chronic Migraine Study Group. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia 2010;30:804-14.
82. Dodick DW, Turkel CC, DeGryse RE, et a. PREEMPT Chronic Migraine Study Group. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache 2010;50: 921-36.
83. Aurora SK, Winner P, Freeman MC, et al. Onabotu- linumtoxinA for treatment of chronic migraine: pooled analyses of the 56-week PREEMPT clinical program. Headache 2011;51:1358-73.
84. Sandrini G, Perrotta A, Tassorelli C, et al. Botulinum tox in type-A in the prophylactic treatment of medication-overuse| headache: a multicenter, double-blind, randomized, placebo-controlled, parallel group study. J Headache Pain 2011;12:427-33.
85. Stensrud P, Skaug OE, Sjaastad O. Clinical trial of MY-25 (1-methyl-ergotamine-bitartrate) in migraine prophylaxis. Headache 1971;11:128-31.
86. Kallanranta T, Hakkarainen H, Hokkanen E, et al.Clonidine in migraine prophylaxis. Headache 1977;17: 169-72.
87. Martin VT. Menstrual migraine: a review of prophylactic therapies. Curr Pain Headache Rep 2004;8:229-37.
88. Sances G, Martignoni E, Fioroni L, et al. Naproxen sodium in menstrual migraine prophylaxis: a double-blind placebo controlled study. Headache 1990;30:705-9.
89. Sullivan E, Bushnell C. Management of menstrual migraine: a review of current abortive and prophylactic therapies. Curr Pain Headache Rep 2010;14:376-84.
90. Pringsheim T, Davenport WJ, Dodick D. Acute treatment and prevention of menstrually related migraine headache: evidence-based review. Neurology 2008 22;70:1555-63.